3 Stocks With Healthy Growth Potential Investors Should Watch

With inflation, interest rates and geopolitical tensions keeping markets on edge, many investors are looking for companies where analysts still see solid earnings growth and balance sheets that can handle bumps in the road. That is exactly what the Healthy high growth potential screener is built to highlight, by filtering for stocks that meet both growth and financial health checks. Instead of chasing every headline, you can focus on a tighter list of candidates that analysts expect to grow earnings over the next 3 years. In this article, you will see 3 of the best stocks currently flagged by this screener.

Dekon Food and Agriculture Group (SEHK:2419)

Overview: Dekon Food and Agriculture Group is a Chengdu based agribusiness that breeds and farms pigs and yellow feathered poultry, selling everything from market hogs and piglets to broiler chickens, feed ingredients and fresh meat products.

Operations: Dekon generates most of its CN¥23.2b revenue from pig sales (about CN¥19.2b), with additional contributions from poultry (around CN¥2.9b) and ancillary products (about CN¥6.8b), primarily in mainland China.

Market Cap: HK$19.9b

Dekon Food and Agriculture Group is notable for investors who focus on earnings driven opportunities in a sector that can be cyclical and sensitive to costs. Analysts currently expect earnings and revenue growth over the next few years, even though profit margins have narrowed from 14.1% to 6.2% and the company has flagged an expected net loss of roughly RMB 1.2b to RMB 1.4b for the first half of 2026. The current P/E of around 12x is below the broader food industry average. Returns on equity are projected to move from about 15.9% to 26.4%, which could influence how the market views the stock if execution improves and financing risks from external borrowing are managed carefully.

Dekon Food and Agriculture Group looks like an earnings story that is out of sync with its current 12x P/E and recent margin pressure, so it is worth seeing how analysts are framing the next chapter in the analyst forecasts for Dekon Food and Agriculture Group

Tomra Systems (OB:TOM)

Overview: Tomra Systems develops sensor based machines and sorting solutions that help collect used bottles and cans, separate waste and metals, and grade food, so that materials can be reused more efficiently instead of going to landfill.

Market Cap: NOK32.6b

Tomra Systems is drawing interest from investors who care about both earnings potential and the long term shift toward recycling, with new deposit return schemes across Europe and the UK potentially expanding demand for its reverse vending machines and services. At the same time, weaker recycling demand, tariff uncertainty and order volatility, especially in the Recycling division, highlight that growth and margins are not guaranteed. Recent contracts to supply thousands of machines into the UK, along with solid revenue progress and expectations for stronger earnings, sit alongside a relatively high P/E and balance sheet risk from heavy external funding. The real question is how these growth contracts, regulatory developments and risks fit together in the medium term for Tomra Systems.

Tomra Systems looks like a growth story tied to recycling policy, but the real tension is how its rich valuation lines up against contract wins and funding pressure, which is unpacked in the analysis report for Tomra Systems

Celcuity (CELC)

Overview: Celcuity is a Minneapolis based clinical stage biotech developing targeted cancer drugs, led by gedatolisib for patients with advanced hormone receptor positive, HER2 negative breast cancer and metastatic castration resistant prostate cancer. The company focuses on turning strong trial data into approved therapies that can be used across several treatment lines for these difficult to treat solid tumors.

Market Cap: US$4.31b

Celcuity is on investors’ radar because gedatolisib, now FDA approved as REVTORPYK for HR+/HER2-, PIK3CA wild type advanced breast cancer, is moving from clinical data into an actual commercial product, with a premium price point and a dedicated sales force preparing for launch. At the same time, Celcuity is still loss making and funding heavy R&D and launch costs with significant external borrowing, so execution risk is real if uptake, payer coverage or further indications such as prostate cancer do not develop as hoped. Analysts currently model rapid revenue growth and a shift to profitability in the coming years, and the key question is whether Celcuity’s trial results, addressable market and balance sheet justify those expectations and the valuation built around them.

Celcuity’s story is accelerating from trial data to real revenues, but the real debate is whether expectations run ahead of reality. That question is exactly what the analyst forecasts for Celcuity quietly tests.

The three stocks covered here are only a starting point, as the full Healthy high growth potential screener has surfaced 1,499 more companies with similarly compelling growth and balance sheet stories in the Healthy high growth potential screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and earnings narratives that matter to you so you can focus on the highest conviction opportunities that fit your approach.

Take Control of Your Investment Journey

If Celcuity or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Markets move fast and the best breakout stories rarely stay under the radar for long. Scan these fresh ideas before the crowd catches on and consider them while they are still in focus.

• Spot potential income anchors by reviewing a curated group of resilient cash generators in the 469 dividend fortresses before yields or valuations shift away from today’s setup.
• Explore structural growth trends by scouting companies involved in AI infrastructure through the targeted 53 AI infrastructure stocks while their stories are still developing and pricing has not fully reacted.
• Look for quality at a discount by assessing financially solid stocks in the focused 225 high quality undervalued stocks before market momentum narrows the gap between price and fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com